Guerbet Achieves Milestone in Vascular Embolization for Lipiodol®

Villepinte-based Guerbet, a leader in medical imaging, has announced a major regulatory milestone in vascular embolization for Lipiodol® Ultra Fluid. The approval follows a worksharing procedure across various EU member states. This new indication aligns Lipiodol® with cyanoacrylate-based glues, enhancing visualization and control in interventional radiology.

This step validates Lipiodol®'s efficacy in minimally invasive procedures. Francois Convenant, SVP Interventional Radiology, highlighted the product's radiopacity and reliability in improving embolization techniques in Europe. Clinicians can now conduct embolization procedures with greater predictability and safety.

Guerbet strengthens its European commitment by offering scientific support and medical education, aiming to improve patient care while maintaining cost efficiency for institutions.